Oral Decitabine/Cedazuridine Vs Intravenous Decitabine for Acute Myeloid Leukemia: Final Results of a Randomized, Crossover, Registration-Enabling, Pharmacokinetics Study

被引：0

作者：

Geissler, Klaus ^{[1
,2
]}

Koristek, Zdenek ^{[3
]}

Del Castillo, Teresa Bernal ^{[4
]}

Novak, Jan ^{[5
,6
]}

Macias, Gabriela Rodriguez ^{[7
]}

Metzelder, Stephan ^{[8
]}

Illes, Arpad ^{[9
]}

Nagy, Agnes ^{[10
]}

Mayer, Jiri ^{[11
,12
]}

Arnan Sangerman, Montserrat ^{[13
]}

Keating, Mary-Margaret ^{[14
]}

Krauter, Juergen ^{[15
]}

Lunghi, Monia ^{[16
]}

Fracchiolla, Nicola ^{[17
]}

Platzbecker, Uwe ^{[18
]}

Santini, Valeria ^{[19
]}

Chan, Danna ^{[20
]}

Mirakhur, Beloo ^{[20
]}

Sano, Yuri ^{[20
]}

Oganesian, Aram ^{[20
]}

Keer, Harold N. ^{[20
]}

Luebbert, Michael ^{[21
]}

机构：

[1] Clin Hietzing, Vienna, Austria

[2] Sigmund Freud Univ, Vienna, Austria

[3] Univ Hosp Ostrava, Ostrava, Czech Republic

[4] Hosp Univ Cent Asturias, ISPA, IUOPA, Oviedo, Spain

[5] Charles Univ Prague, Prague, Czech Republic

[6] Fac Hosp Kralovske Vinohrady, Prague, Czech Republic

[7] Hosp Univ Gregorio Maranon, Madrid, Spain

[8] Philipps Univ Marburg, Marburg, Germany

[9] Univ Debrecen, Dept Hematol, Fac Med, Debrecen, Hungary

[10] Univ Pecs, Pecs, Hungary

[11] Masaryk Univ, Brno, Czech Republic

[12] Univ Hosp Brno, Brno, Czech Republic

[13] Univ Barcelona, Dept Hematol, Inst Catala Oncol, Hosp Duran & Reynals,Inst Invest Biomed Bellvitge, Barcelona, Spain

[14] Queen Elizabeth II QEII Hlth Sci Ctr, Halifax, NS, Canada

[15] Stadt Klinikum Braunschweig, Dept Hematol & Oncol, Braunschweig, Germany

[16] Univ Piemonte Orientale, Dept Translat Med, Div Hematol, Novara, Italy

[17] Fdn IRCCS Ca Granda Osped Maggiore Policlin Milan, Hematol Unit, Milan, Italy

[18] Univ Hosp Leipzig, Dept Hematol, Leipzig, Germany

[19] Univ Florence, DMSC, AOU Careggi, MDS Unit, Florence, Italy

[20] Astex Pharmaceut Inc, Pleasanton, CA USA

[21] Univ Med Ctr Freiburg, Freiburg, Germany

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-173092

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[1] Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study
Geissler, Klaus
Koristek, Zdenek
del Castillo, Teresa Bernal
Novak, Jan
Rodriguez-Macias, Gabriela
Metzelder, Stephan K.
Illes, Arpad
Mayer, Jiri
Arnan, Montserrat
Keating, Mary-Margaret
Krauter, Juergen
Lunghi, Monia
Fracchiolla, Nicola Stefano
Platzbecker, Uwe
Santini, Valeria
Sano, Yuri
Oganesian, Aram
Keer, Harold
Luebbert, Michael
BRITISH JOURNAL OF HAEMATOLOGY, 2024,
[2] The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia
Briski, Robert
Garcia-Manero, Guillermo
Kantarjian, Hagop
Ravandi, Farhad
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2023, 14
[3] Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study
Garcia-Manero, Guillermo
McCloskey, James
Griffiths, Elizabeth A.
Yee, Karen W. L.
Zeidan, Amer M.
Al-Kali, Aref
Deeg, H. Joachim
Patel, Prapti A.
Sabloff, Mitchell
Keating, Mary-Margaret
Zhu, Nancy
Gabrail, Nashat Y.
Fazal, Salman
Maly, Joseph
Odenike, Olatoyosi
Kantarjian, Hagop
DeZern, Amy E.
O'Connell, Casey L.
Roboz, Gail J.
Busque, Lambert
Buckstein, Rena
Amin, Harshad
Randhawa, Jasleen
Leber, Brian
Shastri, Aditi
Dao, Kim-Hien
Oganesian, Aram
Hao, Yong
Keer, Harold N.
Azab, Mohammad
Savona, Michael R.
LANCET HAEMATOLOGY, 2024, 11 (01): : e15 - e26
[4] Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study
Garcia-Manero, Guillermo
Griffiths, Elizabeth A.
Steensma, David P.
Roboz, Gail J.
Wells, Richard
McCloskey, James, II
Odenike, Olatoyosi
DeZern, Amy E.
Yee, Karen
Busque, Lambert
O'Connell, Casey
Michaelis, Laura C.
Brandwein, Joseph
Kantarjian, Hagop
Oganesian, Aram
Azab, Mohammad
Savona, Michael R.
BLOOD, 2020, 136 (06) : 674 - 683
[5] Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study
Bazinet, Alexandre
Garcia-Manero, Guillermo
Short, Nicholas
Alvarado, Yesid
Bataller, Alex
Abuasab, Tareq
Islam, Rabiul
Montalbano, Kathryn
Issa, Ghayas
Maiti, Abhishek
Yilmaz, Musa
Jain, Nitin
Masarova, Lucia
Kornblau, Steven
Jabbour, Elias
Montalban-Bravo, Guillermo
Rausch, Caitlin R.
Pierce, Sherry
Dinardo, Courtney
Kadia, Tapan
Daver, Naval
Konopleva, Marina
Huang, Xuelin
Kantarjian, Hagop
Ravandi, Farhad
LANCET HAEMATOLOGY, 2024, 11 (04): : e276 - e286
[6] A Phase 2 Study of the Fully Oral Combination of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax for Older and/or Unfit Patients with Acute Myeloid Leukemia
Bazinet, Alexandre
Garcia-Manero, Guillermo
Short, Nicholas J.
Valero, Yesid Alvarado
Abuasab, Tareq
Islam, Md Rabiul
Montalbano, Kathryn
Issa, Ghayas C.
Maiti, Abhishek
Yilmaz, Musa
Jain, Nitin
Masarova, Lucia
Kornblau, Steven M.
Jabbour, Elias
Montalban-Bravo, Guillermo
Pierce, Sherry
DiNardo, Courtney D.
Kadia, Tapan M.
Daver, Naval
Konopleva, Marina Y.
Kantarjian, Hagop M.
Ravandi, Farhad
BLOOD, 2023, 142
[7] Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study
Pau Montesinos
Gail J. Roboz
Claude-Eric Bulabois
Marion Subklewe
Uwe Platzbecker
Yishai Ofran
Cristina Papayannidis
Agnieszka Wierzbowska
Ho Jin Shin
Vadim Doronin
Stefan Deneberg
Su-Peng Yeh
Mehmet Ali Ozcan
Steven Knapper
Jorge Cortes
Daniel A. Pollyea
Gert Ossenkoppele
Sergio Giralt
Hartmut Döhner
Michael Heuser
Liang Xiu
Indrajeet Singh
Fei Huang
Julie S. Larsen
Andrew H. Wei
Leukemia, 2021, 35 : 62 - 74
[8] Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study
Montesinos, Pau
Roboz, Gail J.
Bulabois, Claude-Eric
Subklewe, Marion
Platzbecker, Uwe
Ofran, Yishai
Papayannidis, Cristina
Wierzbowska, Agnieszka
Shin, Ho Jin
Doronin, Vadim
Deneberg, Stefan
Yeh, Su-Peng
Ozcan, Mehmet Ali
Knapper, Steven
Cortes, Jorge
Pollyea, Daniel A.
Ossenkoppele, Gert
Giralt, Sergio
Doehner, Hartmut
Heuser, Michael
Xiu, Liang
Singh, Indrajeet
Huang, Fei
Larsen, Julie S.
Wei, Andrew H.
LEUKEMIA, 2021, 35 (01) : 62 - 74
[9] Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study
Bhatnagar, Bhavana
Zhao, Qiuhong
Mims, Alice S.
Vasu, Sumithira
Behbehani, Gregory K.
Larkin, Karilyn
Blachly, James S.
Blum, William
Klisovic, Rebecca B.
Ruppert, Amy S.
Orwick, Shelley
Oakes, Christopher
Ranganathan, Parvathi
Byrd, John C.
Walker, Alison R.
Garzon, Ramiro
LEUKEMIA & LYMPHOMA, 2020, 61 (02) : 387 - 396
[10] Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry
Labrador, Jorge
Martinez-Cuadron, David
de la Fuente, Adolfo
Rodriguez-Veiga, Rebeca
Serrano, Josefina
Tormo, Mar
Rodriguez-Arboli, Eduardo
Ramos, Fernando
Bernal, Teresa
Lopez-Pavia, Maria
Trigo, Fernanda
Martinez-Sanchez, Maria Pilar
Rodriguez-Gutierrez, Juan-Ignacio
Rodriguez-Medina, Carlos
Gil, Cristina
Belmonte, Daniel Garcia
Vives, Susana
Foncillas, Maria-Angeles
Perez-Encinas, Manuel
Novo, Andres
Recio, Isabel
Rodriguez-Macias, Gabriela
Bergua, Juan Miguel
Noriega, Victor
Lavilla, Esperanza
Roldan-Perez, Alicia
Sanz, Miguel A.
Montesinos, Pau
CANCERS, 2022, 14 (09)

← 1 2 3 4 5 →